REGENXBIO Inc. (NASDAQ:RGNX) Q2 2022 Earnings Conference Call August 3, 2022 4:30 PM ET

Company Participants

Vit Vasista - Chief Financial Officer

Ken Mills - President & Chief Executive Officer

Steve Pakola - Chief Medical Officer

Conference Call Participants

Dane Leone - Raymond James

Ellie Merle - UBS

Lisa Walter - RBC Capital Markets

Andreas Argyrides - Wedbush Securities

Mani Foroohar - SVB Securities

Operator

Good day, ladies and gentlemen. Thank you for standing by. Welcome to the Second Quarter 2022 REGENXBIO Inc. Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker’s remarks there will be question-and-answer session. [Operator Instructions]

At this time, I would like to turn the conference over to Mr. Vit Vasista, Chief Financial Officer, REGENXBIO. Sir please begin.

Vit Vasista

Good afternoon and thank you for joining us today. With us today are Ken Mills, REGENXBIO's President and Chief Executive Officer; and Dr. Steve Pakola, our Chief Medical Officer.

Earlier this afternoon, REGENXBIO released financial and operating results for the second quarter ended June 30, 2022. The press release reporting our financial results is available on our website at www.regenxbio.com.

Today's conference call will include forward-looking statements regarding our financial outlook in addition to regulatory and product development plans. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted and can be identified by words such as expect, plan, will, may, anticipate, believe, should, intend and other words of similar meaning. Any such forward-looking statements are not guarantees of future performance and involve certain risks and uncertainties. These risks are described in the risk factors and the management's discussion and analysis sections of REGENXBIO's annual report on Form 10-K for the full year ended December 31, 2021 in comparable risk factors sections in REGENXBIO's quarterly reports on Form 10-Q, which are on file with the Securities and Exchange Commission and available on the SEC's website.

Any information we provide on this conference call is provided only as of the date of this call, August 3, 2022 and we undertake no obligation to update any forward-looking statements we may make on this call on account of new information, future events or otherwise.

Please be advised that today's call is being recorded and webcast. In addition any unaudited or pro forma financial information that may be provided is preliminary and does not purport to project financial positions or operating results of the company. Actual results may differ materially.